Advertisement

Do We Need Antifungal Stewardship?

  • B. Gómez-Gómez
  • P. Cornejo-JuárezEmail author
Treatment and Prevention of Hospital Infections (D Vilar-Compte, Treatment and Prevention of Hospital Infections (D Vilar-Compte, Section Editor)
  • 1 Downloads
Part of the following topical collections:
  1. Topical Collection on Treatment and Prevention of Hospital Infections

Abstract

Purpose of review

Invasive fungal infections (IFIs) are recognized as a significant health problem worldwide. Inappropriate use of antifungals contributes to antifungal resistance and emerging fungi. There is an urgent clinical need to limit inappropriate antifungal usage through judicious antifungal stewardship (AFS).

Recent findings

The main goals of AFS are optimized care, de-escalation or withdrawal of antifungal therapy when appropriate, reduced costs, and reduced fungal resistance, with no negative impact in terms of morbidity or mortality. AFS should be tailored for each institution and health-care system, and should be performed by an experienced and trained multidisciplinary team, based on education, bedside interventions, and daily collaboration with the microbiology department and pharmacy team. Performance measures are needed to evaluate the impact of AFS. It is recommended that AFS be implemented in a stepwise manner, with modest initial goals to enable demonstration of success in the short term.

Summary

Encouraging the appropriate use of antifungal drugs should help to decrease the incidence of IFIs, thereby reducing antifungal resistance.

Keywords

Antifungal Stewardship Invasive fungal infections Diagnosis Fungal resistance 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wattal C, Cakrabarti A, Oberoi JK, Donnelly JP, Barnes RA, Sherwal BL, et al. Issues in antifungal stewardship: an opportunity that should not be lost. J Antimicrob Chemother. 2016;72:969–74.  https://doi.org/10.1093/jac/dkw506.Google Scholar
  2. 2.
    Whitney L, Bicanic T. Antifungal stewardhisp. In: Laundy M, Gilchrist M, Whitney L, editors. Antimicrobial stewardship. Oxford: University Press; 2016. p. 1–20.Google Scholar
  3. 3.
    Stanzani M, Sassi C, Battista G, Cavo M, Lewis RE. Improved radiographic imaging of invasive fungal disease: the cornerstone to antifungal stewardship in the hematology units? Curr Fungal Infect Rep. 2016.  https://doi.org/10.1007/s12281-016-0258-1.
  4. 4.
    Azap OK, Ergönül O. Antifungal stewardship. In: Pulcini C, Ergönuül Ö, Beovic B, Can F, editors. Antimicrobial stewardship. Amsterdam: Elsevier; 2017. p. 147–63.CrossRefGoogle Scholar
  5. 5.
    •• Urbancic KF, Thursky K, Kong DCM, Johnson PDR, Slavin MA. Antifungal stewardship: developments in the field. Curr Opin Infect Dis. 2018;31:490–8.  https://doi.org/10.1097/QCO.0000000000000497 This very recent article very clearly describes the fundamental aspects of implementing a stewardship program.Google Scholar
  6. 6.
    Ramos A, Pérez-Velilla C, Asensio A, Ruiz-Antorán B, Folguera C, Cantero M, et al. Antifungal stewardship in a tertiary hospital. Rev Iberoam Micol. 2015;32:209–13.  https://doi.org/10.1016/j.riam.2014.11.006.CrossRefGoogle Scholar
  7. 7.
    Gamaletsou MN, Walsh TJ, Sipsas NV. Invasive fungal infections in patients with hematological malignancies: emergence of resistant pathogens and new antifungal therapies. Turk J Hematol. 2018;35:1–11.  https://doi.org/10.4274/tjh.2018.0007.CrossRefGoogle Scholar
  8. 8.
    Vallabhaneni S, Baggs J, Tsay S, Srinivasan AR, Jernigan JA, Jackson BR. Trends in antifungal use in US hospitals, 2006-12. J Antimicrob Chemother. 2018;73:2867–75.  https://doi.org/10.1093/jac/dky270.CrossRefGoogle Scholar
  9. 9.
    Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. Virulence. 2017;8:658–72.  https://doi.org/10.1080/21505594.2016.1226721.CrossRefGoogle Scholar
  10. 10.
    Valerio M, Vena A, Rodríguez-González CG, de Vega EC, Mateos M, Sanjurjo M, et al. Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship. Eur J Clin Microbiol Infect Dis. 2018;37:1993–2000.  https://doi.org/10.1007/s10096-018-3335-2.CrossRefGoogle Scholar
  11. 11.
    Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D, Enoch DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J Antimicrob Chemother. 2015;70:1908–11.  https://doi.org/10.1093/jac/dkv040.Google Scholar
  12. 12.
    Aguado JM, Silva JT, Bouza E. Conclusion and future perspectives on antifungal stewardship. J Antimicrob Chemother. 2016;71(suppl 2):ii43–4.  https://doi.org/10.1093/jac/dkw396.CrossRefGoogle Scholar
  13. 13.
    Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuet AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:e51–77.  https://doi.org/10.1093/cid/ciw118.CrossRefGoogle Scholar
  14. 14.
    Ruhnke M. Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect. 2014;20(Suppl 6):11–8.  https://doi.org/10.1111/1469-0691.12622.CrossRefGoogle Scholar
  15. 15.
    Nwankwo L, Periselneris J, Cheong J, Thompson K, Darby P, Leaver N, et al. A prospective real-world study of the impact of an antifungal stewardship program in a tertiary respiratory-medicine setting. Antimicrob Agents Chemother. 2018;62(10).  https://doi.org/10.1128/AAC.00402-18.
  16. 16.
    Richardson MD. An introduction to antifungal stewardship. Antimicrob Chemother. 2016;71(suppl 2):ii3.  https://doi.org/10.1093/jac/dkw390.CrossRefGoogle Scholar
  17. 17.
    Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17:e383–92.  https://doi.org/10.1016/S1473-3099(17)30316-X.CrossRefGoogle Scholar
  18. 18.
    Muñoz P, Bouza E. The current treatment landscape: the need for antifungal programmes. J Antimicrob Chemother. 2016;71(Suppl 2):ii5–ii12.  https://doi.org/10.1093/jac/dkw391.CrossRefGoogle Scholar
  19. 19.
    •• Muñoz P, Valerio M, Vena A, Bouza E. Antifungal stewardship in daily practice and health economic implications. Mycoses. 2015;58(Suppl 2):14–25.  https://doi.org/10.1111/myc.12329 This manuscript provides a step-by-step guides for the successful implementation of an AFS program.CrossRefGoogle Scholar
  20. 20.
    Agrawal S, Barnes R, Brüggemann RJ, Rautemaa-Richardson R, Warris A. The role of the multidisciplinary team in antifungal stewardship. J Antimicrob Chemother. 2016;71(suppl 2):ii37–42.  https://doi.org/10.1093/jac/dkw395.CrossRefGoogle Scholar
  21. 21.
    • Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.  https://doi.org/10.1086/510393. These are the guidelines issued by the IDSA which support programs for use of antimicrobials, including antifungals.CrossRefGoogle Scholar
  22. 22.
    Pfaller MA, Castanheira M. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol. 2016;54:1–22.  https://doi.org/10.1093/mmy/myv076.Google Scholar
  23. 23.
    Rouzé A, Loridant S, Poissy J, Dervaux B, Sendid B, Cornu M, et al. Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med. 2017;43:1668–77.  https://doi.org/10.1007/s00134-017-4932-8. CrossRefGoogle Scholar
  24. 24.
    Hull CM, Purdy NJ, Moody SC. Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help? Future Microbiol. 2014;9:307–25.  https://doi.org/10.2217/fmb.13.160.CrossRefGoogle Scholar
  25. 25.
    Miyazaki T, Kohno S. Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis. Expert Rev Anti-Infect Ther. 2015;13:1171–83.  https://doi.org/10.1586/14787210.2015.1058157.CrossRefGoogle Scholar
  26. 26.
    Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146–51.  https://doi.org/10.1093/jac/dkr244.CrossRefGoogle Scholar
  27. 27.
    Cornely OA, Koehler P, Arenz D, Mellinghoff SC, et al. EQUAL Aspergillosis Score 2018: an ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. Mycoses. 2018;61:833–6.  https://doi.org/10.1111/myc.12820.CrossRefGoogle Scholar
  28. 28.
    Rzewuska M, Charani E, Clarkson JE, Davey PG, Duncan EM, Francis JJ, et al. Prioritizing research areas for antibiotic stewardship programmes in hospitals: a behavioural perspective consensus paper. Clin Microbiol Infect. 2019;25:163–8.  https://doi.org/10.1016/j.cmi.2018.08.020.CrossRefGoogle Scholar
  29. 29.
    Valerio M, Muñoz P, Rodríguez CG, Caliz B, Padilla B, Fernández-Cruz A, et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clin Microbiol Infect. 2015;21:492.e1–9.  https://doi.org/10.1016/j.cmi.2015.01.013.CrossRefGoogle Scholar
  30. 30.
    Valerio M, Rodriguez-Gonzalez CG, Muñoz P, Caliz B, Sanjurjo M, Bouza E, et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother. 2014;69:1993–9.  https://doi.org/10.1093/jac/dku053.CrossRefGoogle Scholar
  31. 31.
    Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162–76.  https://doi.org/10.1093/jac/dkt508.CrossRefGoogle Scholar
  32. 32.
    Bal AM, Shankland GS, Scott G, Imtiaz T, Macaulay R, McGill M. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. Int J Clin Pract. 2014;68:20–7.  https://doi.org/10.1111/ijcp.12231.CrossRefGoogle Scholar
  33. 33.
    Lempers VJ, Brüggemann RJ. Antifungal therapy: drug-drug interactions at your fingertips. J Antimicrob Chemother. 2016;71:285–9.  https://doi.org/10.1093/jac/dkw159.CrossRefGoogle Scholar
  34. 34.
    Barnes RA, Stocking K, Bowden S, Poynton MH, White PL. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. J Infect. 2013;67:206–14.  https://doi.org/10.1016/j.jinf.2013.04.020.CrossRefGoogle Scholar
  35. 35.
    Morii D, Ichinose N, Yokozawa T, Oda T. Impact of an infectious disease specialist on antifungal use: an interrupted time-series analysis in a tertiary hospital in Tokyo. J Hosp Infect. 2018;99:133–8.  https://doi.org/10.1016/j.jhin.2018.01.003.CrossRefGoogle Scholar
  36. 36.
    Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25:107–15.  https://doi.org/10.1097/QCO.0b013e32834e0680.CrossRefGoogle Scholar
  37. 37.
    Bienvenu AL, Argaud L, Aubrun F, Fellahi JL, Guerin C, Javouhey E, et al. A systematic review of interventions and performance measures for antifungal stewardships programmes. J Antimicrob Chemother. 2018;73:297–305.  https://doi.org/10.1093/jac/dkx388.CrossRefGoogle Scholar
  38. 38.
    López-Medrano F, Juan RS, Lizasoain M, Catalán M, Ferrari JM, Chaves F, et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect. 2013;19:56–61.  https://doi.org/10.1111/j.1469-0691.2012.03891.x.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Infectious DiseasesInstituto Nacional de Cancerología (INCan)México CityMéxico

Personalised recommendations